1 / 14

Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by 2024

For more Info: <br>https://www.renub.com/global-liquid-biopsy-market-nd.php<br><br>Liquid Biopsy is a non-invasive technology which is used in the detection of molecular biomarkers without the need for invasive or costly surgical procedures. Liquid Biopsy is a simple and an alternative method to surgical biopsies which helps physicians to discover a range of information about a tumor or a disease through a simple blood, urine, saliva or cerebrospinal fluids sample. Circulating cancer cells or traces of the cancer’s DNA or DNA in the fluid sample can give indication about the treatments that a patient likely to need. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024. <br><br>Request a free sample copy of the report: <br><br>https://www.renub.com/contactus.php <br><br>Increasing Cancer Incidences<br>On an estimate nearly 14.1 million people suffered from cancer around the world in 2012, of which 7.4 million were men and 6.7 million women. The incidence of cancer seems to be increasing with increasing per capita income. Asia, Europe and Americas are some of the regions where highest incidences of cancer occur. Lung Cancer, Colorectal Cancer and Breast Cancer are among the most prevalent types of cancer worldwide.<br> <br>Client can Purchase this Report in Sections from below link:<br><br>Access full Research: <br><br>https://www.renub.com/liquid-biopsy-market-p.php<br><br><br>Due to the rising prevalence of cancer and the complexity of cancer’s treatment, demand for liquid biopsy test is increasing more rapidly during the patient’s care than ever before. The liquid biopsy test is basically the analysis of various analytes, namely Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (Exosomes), miRNA, mRNA and Proteins. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) have been the most analyzed and commercially developed medical technologies amongst these analytes.<br>

renubresearch
Download Presentation

Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category: Diagnostics Market Report

  2. Global Liquid Biopsy Market Analyst View: • Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024. • Get Free Customization in this Report • Press Release Title: • Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by 2024. • For more Info: • https://www.renub.com/global-liquid-biopsy-market-nd.php

  3. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024. • Research Report Title: • Liquid Biopsy Market, Global Analysis by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen) • Access Full Research: • https://www.renub.com/liquid-biopsy-market-p.php

  4. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024. Liquid Biopsy is a non-invasive technology which is used in the detection of molecular biomarkers without the need for invasive or costly surgical procedures. Liquid Biopsy is a simple and an alternative method to surgical biopsies which helps physicians to discover a range of information about a tumor or a disease through a simple blood, urine, saliva or cerebrospinal fluids sample. Circulating cancer cells or traces of the cancer’s DNA or DNA in the fluid sample can give indication about the treatments that a patient likely to need. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024.  Increasing Cancer Incidences On an estimate nearly 14.1 million people suffered from cancer around the world in 2012, of which 7.4 million were menand 6.7 million women. The incidence of cancer seems to be increasing with increasing per capita income. Asia, Europe and Americas are some of the regions where highest incidences of cancer occur. Lung Cancer, Colorectal Cancer and Breast Cancer are among the most prevalent types of cancer worldwide.

  5. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024.

  6. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024. Request a free sample copy of the report: https://www.renub.com/contactus.php Due to the rising prevalence of cancer and the complexity of cancer’s treatment, demand for liquid biopsy test is increasing more rapidly during the patient’s care than ever before. The liquid biopsy test is basically the analysis of various analytes, namely Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (Exosomes), miRNA, mRNA and Proteins. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) have been the most analyzed and commercially developed medical technologies amongst these analytes. Use of Liquid Biopsy in Oncology In regards to both cancer diagnosis and its treatment, liquid biopsy is one of the most significant techniques. Personalized or precision medicine is one of the categories in oncology care which focuses more on a patient’s genetic profile to target their cancer. Regrettably, all cancers are not same and so, one treatment for all – ‘One Size Fits All’ may cause more harm than anything good. Using a liquid biopsy can help determine whether the ongoing treatment is effective or not. 

  7. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024. Cancerous tumors can be stony by the treatment in the past. Acquired resistance is one of the major obstructions in eliminating cancer using drugs and treatments like radiation, which have huge side effects. These treatment resistances can easily be detected using a liquid biopsy test. Using precision medicine such as genetic mutations (ctDNA), is a process which can limit the associated dangers of such treatments.  These days, patient’s cancer treatment is shifting from non-specific, cytotoxic chemotherapy to more specific, targeted therapies or immunotherapy; which focus more on the precise genetic characteristics of the patients that are identified either by liquid biopsy or tissue methods earlier to or during the cancer therapy. Also, companies around the world plan to develop more affordable fluids based (liquid biopsy) cancer screening tests to detect cancer in early stages. With the recent advancement in medical science, it is expected that liquid biopsy tests will become cost-efficient and will certainly exert liquid biopsy market to grow further in the near future. 

  8. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024. • Client can Purchase this Report in Sections from below link: • Access full Research:https://www.renub.com/liquid-biopsy-market-p.php • Global Liquid Biopsy Market Summary • Lung Cancer Controls the Liquid Biopsy Market. On the basis of cancer segments report studies the market of Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. • Based on product type 90% of liquid biopsy market is comprised by kits & Consumables and Instruments. The covers the market of Kits & consumables, Instruments and Services. • On the basis of Clinical Application Screening Purpose controls the Liquid Biopsy Market. The study provides the data on the following segments Monitoring, Prognosis, Theranostics & Screening. • .

  9. Liquid Biopsy Market is projected to surpass US$ 3.4 Billion by the end of year 2024. • Region-wise Europe and North America is expected to drive the Global Liquid Biopsy Market. Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Markets are also studied in the report. •  On the basis of Sample Plasma/Serum accounts for the highest market compared to Urine and Others.  • The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. • The competitive landscape of the market has also been examined with some of the key players being Qiagen, Roche Diagnostics, Myriad Genetics, Inc., Thermo Fisher Scientific Inc., Genomic Health, Bio-Rad Laboratories Inc., NeoGenomics Laboratories, Biocartis and Biocept Inc.,   • If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at info@renub.com

  10. Table of Contents for Global Liquid Biopsy Market Key Topics Covered 1.    Executive Summary 2.    Global - Liquid Biopsy Market 3.    Market Share – Global Liquid Biopsy 3.1    By Region 3.2    By Cancer3.3    By Product 3.4    By Circulating Biomarkers 4.    Region - Liquid Biopsy Market 4.1    North America 4.2    Europe4.3    Asia-Pacific 4.4    Latin America4.5    Middle East & Africa 5.    Cancer - Liquid Biopsy Market 5.1    Lung Cancer 5.2    Breast Cancer5.3    Colorectal Cancer 5.4    Prostate Cancer5.5    Others

  11. Table of Contents for Global Liquid Biopsy Market 6.    By Product - Liquid Biopsy Market 6.1    Kits & Consumables 6.2    Instruments6.3    Services 7.    Circulating Biomarkers - Liquid Biopsy Market 7.1    Circulating Tumor Cells (CTCs) 7.2    Circulating Tumor DNA (ctDNA)7.3    Exosomes 8.    By Clinical Application - Liquid Biopsy Market 8.1    Monitoring 8.2    Prognosis8.3    Theranostics 8.4    Screening 9.    By Sample - Liquid Biopsy Market 9.1    Plasma / Serum 9.2    Urine9.3    Others 10.    Thermo Fisher Scientific Inc – Company Analysis 10.1    Product Portfolio

  12. Table of Contents for Global Liquid Biopsy Market 11    Roche Diagnostics – Company Analysis 11.1    Product Portfolio 12.    Bio-Rad Laboratories Inc – Company Analysis 12.1    Product Portfolio 13.    Biocept, Inc. – Company Analysis 13.1    Product Portfolio 13.2    Financial Insight 14.    Biocartis – Company Analysis 14.1    Product Portfolio 14.2    Financial Insight 15.    Myriad Genetics, Inc – Company Analysis 15.1    Product Portfolio 15.2    Financial Insight 16.    Genomic Health – Company Analysis 16.1    Product Portfolio 16.2    Financial Insight

  13. Table of Contents for Global Liquid Biopsy Market 17.    NeoGenomics Laboratories – Company Analysis 17.1    Product Portfolio 17.2    Financial Insight 18.    Qiagen – Company Analysis 18.1    Product Portfolio18.2    Financial Insight 19.    Growth Drivers 19.1    Real-Time Evaluation, Convenient and Accuracy19.2    Increasing Demand for Minimally-Invasive Biopsy Techniques19.3    Technical Advancement & Personalized Therapies 20.    Challenges 20.1    Barriers for Liquid Biopsies20.2    High Cost with Uncertain or Limited Reimbursement for Liquid Biopsy

  14. GetFree Customization in this Report • Diagnostics Market Reports: • https://www.renub.com/diagnostics-14-c.php

More Related